Terrie Livingston

Burden of multiple sclerosis on direct, indirect costs and quality of life: National US estimates

Jonathan D. Campbell, Vahram Ghushchyan, R. Brett McQueen et al. · Multiple Sclerosis and Related Disorders · 2013 · 129 citations

Pharmacy, Neurology, Pharmacoeconomics +16

Comparative effectiveness of dimethyl fumarate versus fingolimod and teriflunomide among MS patients switching from first-generation platform therapies in the US

Daniel Ontaneda, Jacqueline Nicholas, Matthew Carraro et al. · Multiple Sclerosis and Related Disorders · 2018 · 58 citations

Pharmacy, Pharmacotherapy, Clinical Pharmacology +16

Cost-effectiveness of delayed-release dimethyl fumarate for the treatment of relapsing forms of multiple sclerosis in the United States

Josephine Mauskopf, Monica Fay, Ravi Iyer et al. · Journal of Medical Economics · 2015 · 32 citations

Pharmacy, Neurology, Pharmacoeconomics +17

The cost-effectiveness of disease-modifying therapies for the treatment of relapsing-remitting multiple sclerosis

Duygu Bozkaya, Terrie Livingston, Kristen Migliaccio–Walle et al. · Journal of Medical Economics · 2016 · 30 citations

Pharmacy, Neurology, Pharmacoeconomics +17

Perceptions and Preferences Regarding Multiple Sclerosis Research Among Racial and Ethnic Groups

Daniela Pimentel Maldonado, April Moreno, Mitzi Williams et al. · International Journal of MS Care · 2021 · 28 citations · Full text

Public Health, Population Health Sciences, Community Engagement +12